Statistics provides an important tool to enable large amounts of data from an experiment to be summarised and conclusions drawn. To be informative statistics need to serve the experimenter appropriately and give clear and understandable answers. It is important that the reader can clearly understand the methodology used, and that that methodology is appropriate to the situation. We present here some issues to be considered when writing for publication in the British Journal of Haematology (BJH).
Introduction
There can be few scientific areas that provoke such a violent reaction in many people as statistics. It feels sometimes that there can be no middle ground -either one subscribes to the view that statistics are unnecessary or, at best, an inconvenience, echoing the aphorism commonly ascribed to Ernest Rutherford that if one needs statistics one should have designed a better experiment; or, less commonly (and probably exclusively among statisticians), that statistics is a form of € uber science, without which all other work is worthless. However, both camps do agree that statistics appears complicated and somewhat impenetrable -a major triumph for the statistician who can create job security by stressing the complex nature of their work.
But this is to misunderstand the real purpose of statistics in medical research. It is a tool -sometimes a specialist tool -but a means to an end and not an end in itself. We can design better (i.e. more complex) methods, but at the end of the day, the statistics should provide illumination, and enable a usually vast amount of data to be summarised. Like any other piece of equipment, statistics can be misused, either consciously or unconsciously. The Journal views statistics as an important way of demonstrating the weight and strength of evidence to answer any scientific hypothesis, and statistical review is at the heart of the paper review process. Done well, statistics can help the reader see through a thicket of data; done badly it can lead to obfuscation, misdirection and just plain wrong answers.
Guidelines on statistical analyses are not hard to come by, and the issue of statistical reporting goes back many years (e.g. O'Fallon et al, 1978; Moher et al, 2001; Altman et al, 1983 ; International Committee of Medical Journal Editors [ICMJE], 2015; Lang & Altman, 2013) . They all share the same aim: to ensure that the reader can be sure of what has been done and that conclusions drawn are supportable by the data. With that in mind, we present here a personal selection of key dos and don'ts for writing for publication in BJH. Not all may be applicable to all scenarios, but they represent some of the most common issues found in statistical review of manuscripts.
Do explain the methods
Like other occult techniques of divination, the statistical method has a private jargon deliberately contrived to obscure its methods from non-practitioners.
G.O. Ashley
With statistics being viewed as a somewhat occult art, it is important that the statistical methods are given in sufficient clarity. The ICMJE makes the point that authors should 'describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results ' (ICMJE, 2015) . Authors should ensure that all tests are described in the methods section, together with the important issue of how the sample was determined in the first place (which patients, how many -and why that number were included). The methods section must describe the design of the experiment and in particular the original hypotheses -what the main question; was and what size of effect was considered worthwhile in the first place. These details should be present in the original protocol for the experiment. It is helpful to specify the software used to analyse the data.
Most analytical approaches are based upon assumptions. The fundamental assumption in doing a statistical test is that there is no bias -no systematic difference that can confound any comparison. This will be returned to later. Additionally, however, there are often assumptions that underpin the test used. For example, the use of a Student t-test implies near Normality of the data [although the test itself is relatively robust (Altman & Bland, 1995) ]. It is attractive to transform the variable to make it look more Normal (e.g. comparing log cell counts rather than actual counts). But any transformations need to be justified and biologically plausible, rather than just being the best way to get Normality, and methods for dealing with outliers -if any -specified. In transforming, the effect on confidence intervals needs to be understood as well -for this reason the logarithmic transformation is one of the easiest to work with (Bland & Altman, 1996) .
By and large, methods should be explained in relatively simple terms; they are not the centrepiece but the necessary accompaniment to the results. The plausibility of the results is greater with a method that is clear and 'understanded of the people', than if it appears that a complex black box has been used.
One final point -the symbol AE is confusing -does it refer to the standard deviation, 1Á96 times the standard deviation, the standard error or 1Á96 times the standard error? Its use should be eschewed.
A necessary corollary of the above is that if a method relies on assumptions, then these assumptions need to be tested. Don't rely on P-values -confidence intervals are more informative -but do report them fully
It is attractive to think that the results of an experiment can be boiled down to a simple, easy to communicate messagenot just a headline result, but a tabloid headline result. At first sight the P-value appears to do just that: to dichotomise into significant and not significant. But there are issues with this approach. The P-value is a measure of the strength of the evidence provided; a very small study will give only a little evidence, and will only be significant if an effect is very large. By contrast a very large study should provide a lot of evidence one way or the other, and will be significant with only a small effect. To dichotomise these can lead to wrong interpretation: a very small, but significant effect may not be clinically relevant, and a small study may miss a real but moderate effect. For this reason, wherever possible, estimates of any effect and confidence intervals should be given. Not only does this mean that any conclusions are based upon our estimate and our level of uncertainty, but also that data from many studies can be more accurately combined to give a complete overview of the field. It is still helpful to report P-values (and sometimes these are all that can be reported), but these should be given exactly. Importantly, all tests performed must be reported, not just the significant ones, to avoid accusations of chasing significance or cherry picking.
Importantly, non-significant and equivalent are not synonymous. Non-significant means there is no evidence of difference; equivalent means there is evidence that any difference is too small to be clinically relevant. A small study will tend to be non-significant but cannot rule out a meaningful difference, as evinced in the confidence intervals.
Don't vote count
Summarising a lot of data can be difficult, and this can be even more fraught when combining information in a review from a lot of studies. It is often tempting to look at how many studies found a 'positive' (i.e. statistically significant) result, and the number with a negative result. But this ignores two important issues. First, not all studies are created equal. Some may be better designed than others; but even if the design is the same, some will be larger than others. Secondly, as described above, a P-value is not a dichotomous thing. It doesn't delineate between works and doesn't work. It merely says how strong the evidence is. So vote counting can lead to misleading results [famously seen in the meta-analysis of the results of tamoxifen trials in the 1980s; Early Breast Cancer Trialists Collaborative Group (EBCTCG) 1990]. Figure 1 shows some possible scenarios where vote counting and the results of a proper metaanalysis give conflicting answers. It is not just the number of studies, but the weight of those studies' evidence that counts. It is relatively easy to produce a simple Forest plot and metaanalysis of results; if results can be combined (i.e. the reporting is sufficiently detailed and sufficiently similar), then this should be considered in all reviews synthesising the results of many studies. Of course, it goes without saying that participants (or samples) should only be included once -generally the most complete or most up to date reference only should be used unless one can unpick the different datasets.
Don't test at baseline in an RCT
In reporting any experiment, it is important to document the subjects in the experiment -be they people, animals, samples, etc. A table of baseline characteristics is a good way to display the information and is indeed recommended in the Consolidated Standards of Reporting Trials (CONSORT) statement on randomised trials (Moher et al, 2001 ). However, they go on to add that 'significance testing of baseline differences in randomized controlled trials (RCTs) should not be performed, because it is superfluous and can mislead investigators and their readers'. If randomisation was performed properly then any differences that are seen in this sort of test must have occurred by chance, so testing to see if they occurred by chance is perverse (Altman, 1985; De Boer et al, 2015) .
Don't trust historical controls
Every day in every way, I am getting better and better.
Emile Cou e How does one evaluate the impact of a new treatment? The gold standard is the randomised controlled trial (Collins et al, 2003; Akobeng, 2005) , but these are time consuming, expensive and, occasionally, not feasible in small populations. One option is to measure the impact of changing treatment by comparing the time period before the introduction of the treatment to the period after it was introduced. But this approach is fraught with difficulties. Comparing eras doesn't take into account other things that might change over timecase mix, supportive care, etc. A cautionary tale is given by the Same as Before (SAB) regimen (Wheatley, 2002) . Wheatley found that SAB improved remission outcomes in older patients with acute myeloid leukaemia (AML), from 47% to 61% compared to daunorubicin/ara-C (cytarabine)/thioguanine (DAT). However, the three-drug regimen SAB was 'Same As Before' (i.e. DAT): comparison was between two successive UK Medical Research Council trials in AML (AML9, AML11). Even after adjustment for known factors, the difference remained highly significant. The improvement is not then due to known differences in patients, but instead unknowable differences, such as supportive care. Don't compare apples and oranges
The above example demonstrates an important issue with 'as treated' analyses. Not all treatments are suitable for all patients, and so one is comparing a selected group of patients with, say renal or hepatic or cardiac exclusions, with all-comers. The comparison is immediately not fair and statistics cannot allow for it, as it cannot measure the decision process exactly. Care also needs to be taken in looking at case-control studies. Not only the selection factors for the cases need to be taken into account but also the controls (Wacholder et al, 1992) . It is important to know that they are comparable and that similar eligibility is in both groups. For this reason, a 'convenience sample' of controls -those readily available-may not give reliable answers.
Do be aware of bias
The types of systematic differences seen above are examples of selection bias -the groups being compared are not, in fact, comparable. This is perhaps the most common source of bias; yet others are important also. Performance bias is when the groups being compared have other differing aspects (e.g. different laboratory protocols, or even different laboratories); ascertainment bias is when the different groups are assessed differently -a trial of minimal residual disease (MRD) monitoring versus no MRD monitoring may show the monitoring arm as giving worse relapse-free survival, because relapses are picked up earlier, and some relapses aren't picked up and are reported as deaths in remission; attrition bias is when the groups have dropouts at different stages -e.g. when a patient stops protocol treatment, their follow-up stops also. By the time it comes to reporting many of these problems cannot be fixed so it is important to ensure as complete follow-up as possible, standardised protocols and a choice of endpoints that are not going to be influenced by ascertainment bias (e.g. survival in the case of MRD monitoring versus not). Statistics cannot unfortunately reliably rescue these sorts of problems. One subtler form of bias is 'immortal time bias' (Sylvestre et al, 2006) . When comparing a treatment such as stem cell transplant, which has a lead time, it is not correct to compare the transplanted with the non-transplanted group, because early deaths in people for whom transplant is intended will count against the non-transplant groups. The time to transplant needs to be allowed for, using methods such as landmark analysis (excluding all events before a certain time point), or MantelByar analysis (Mantel & Byar, 1974) where patients start in the no transplant group and switch at the time of transplant. However, these methods do not allow for selection factors that influence the decision to transplant in the first place, such as relapse risk and fitness, which may well act against each other and produce unquantifiable bias.
Don't abandon intention to treat without good reason
The underlying principle behind intention to treat (ITT) in clinical trials is to remove selection bias (Collins et al, 2003) . Randomisation has created similar groups, but non-compliance means that the people who comply with the protocol may not only be different from those who did not, but also between the different treatment arms of the study. Intentionto-treat analysis keeps the randomised groups intact, but requires follow-up of all patients, irrespective of compliance or adherence. ITT is termed a 'conservative' analysis -in that if a difference is seen, even after protocol deviations, then the difference is likely to be real. The exception to ITT analysis comes when one wants to rule out a difference -to consider toxicity, or in the case of an equivalence or noninferiority trial. In those cases, low levels of compliance will tend to reduce rates of adverse events, and any differences will be artificially reduced, giving potential apparent equivalence -a 50% toxicity rate with only 20% compliance would appear to give a 10% toxicity rate, which may be misleading. The issue of performing meaningful ITT analysis is something that needs to be considered carefully at the design stage of the experiment: in randomised trials, performing randomisation as close as possible to the point of treatment divergence, and ensuring as complete data collection as possible can improve the reliability of results.
Don't use plots when they don't add anything -don't use the 'dynamite' plot
Wading through a sea of numbers can be daunting, and even tables do not always convey a message in a simple fashion. The lure of the figure is strong, and many figures can illuminate, telling a story in an attractive and easily absorbed fashion. But not all data is better as a figure. Figure 2 shows two examples. The pie chart in Fig 2A has no denominator, so the data are not given completely. Information is missing; and when one adds the information, as in Fig 2B, there is nothing that could not be given more economically in the text. Figure 2C illustrates one of the most common, but also potentially most misleading types of figure, the so-called dynamite plot. The column gives the mean and the whisker or plunger the standard deviation. As such the graph gives no more information than could be given economically in the text, so it is a wasted figure. Yet it can also mislead. The first column could be produced by either of the data distributions in Fig 2d, 
Don't dichotomise for the sake of it
Much of elementary statistical analysis is framed in terms of comparing two groups (for example, the t-test, or the 2 9 2 contingency table). The idea of a difference between two groups is intrinsically appealing, and lends itself to simple presentation in tabular or graphical form. But there are numerous drawbacks to dichotomisation of continuous variables (Altman & Royston, 2006 ). At the very simplest level, information has been lost as with dichotomisation there is no distinction between small and very small. So, one could lose power and miss important effects. But, the choice of the cutoff point for dichotomisation can also introduce issues. It is clearly inappropriate to choose the 'best' cut-off point based upon the data being analysed, because this will artificially improve significance; choosing the median means that each study performed will have a different cut-off point. In analyses such as regression, there is no need to dichotomise; the method is designed to work with continuous variables, and transformation is often a better option than dichotomisation.
Do bear in mind multiple testing
A P-value represents the chances that the data observed, or some more extreme, may have been seen by chance. Put more simply, on average, one in every 20 randomised trials of treatment A versus treatment A (i.e. with no differential treatment effect whatsoever) will be significant at P < 0Á05.
Better trial registration means that we can be surer that trials are not being repeated until a significant result is obtained. But the same problem applies with multiple outcomes within the same trial, or multiple exposures. In a study with many genes, one in 20 will be significant at P < 0Á05, and if the study is small, then these will necessarily appear to have a large effect. Care needs to be taken to control the overall false positive rate; either adjustment needs to be made, or a primary outcome or exposure identified. Alternatively, studies can be split into discovery and validation cohorts -only those significant in the discovery cohort are tested in the validation cohort. This is particularly important when a new prognostic index is obtained. It is, by definition, the best fit for the data set it was derived on; validation shows that it is, in general, an improvement, rather than a quirk of the dataset used.
Do keep an eye on the primary outcome and question
It has been pointed out above that reports should state the underlying hypothesis (or hypotheses). This will typically have been framed in terms of a small number (ideally one) of primary outcomes. These are the pre-specified most important questions, and effectively those by which the study stands or falls. Even a non-significant result can be important, but to attempt to find something 'interesting' is alluring. Secondary outcomes can be interesting and, in particular, hypothesis generating, but the abstract and results section should lead with the primary hypothesis. Without such primary hypotheses, the report can fall into the trap of multiple testing.
Don't stress subgroups
Similarly, looking at the same hypothesis in several different subgroups also increases the chances of a false positive. Any test of subgroups should include an appropriate test for interaction. It is not correct merely to compare the P-values between the subgroups and dichotomise (Assmann et al, 2000; Wang et al, 2007) . However, over and above these considerations, it is important to consider whether data are paired or independent. Paired data are familiar, when considering two readings on the same individual (e.g. before and after) -and the need for different tests well known -but the situation also arises in case-control studies. It is important there to state whether pairing has been done at the individual level -i.e. recruiting a control with features matching those of a case. If this has been done, then the methodology is different from a standard case-control study where there is no individual level matching.
Do ensure the test matches the data
Comparing changes from baseline between two groups, however, is not paired -the comparison is between groups and the variable is the change. It is not correct to see if there is a significant change in each group and then draw conclusions based on the P-values -the correct test between independent groups on the change from baseline needs to be done. Taking this concept one stage further, suitable methods need to be used for repeated measures data where the same quantity is measured over time. Again, merely testing at lots of different time points raises issues of multiple testing -but also each individual test will have less power to detect a difference than one which takes all the data into account at once.
Do calculate median survival/follow-up correctly -but don't rely on them to give a full picture A median is a well-understood, and simply communicated idea. Half the population do better than the median and half do worse. Median survival is exactly that -the time when you expect half the population to have died. This can be calculated using standard Kaplan-Meier techniques, and is where the survival function crosses 50%. It is not the median of the times of the events calculated only on the patients having an event. If only a minority of people relapse, the median time to relapse may not have been reached -it is not the median time among relapsing patients, but needs to be calculated using cumulative incidence techniques with death as competing risk. Similarly, when computing median follow-up, the reverse censoring method should be used (Machin et al, 2006) , rather than looking at the median of all survival times censored or not, or only those patients who have not had an event.
Medians are an attractive shorthand for survival. But they can mislead. For a procedure that is kill or cure, and each are equally likely, there is a high risk of early death, but the prospects if one survives are infinite. The median tells us the former, but not the latter. Medians do not tell the whole story when there is a cure percentage. For curves that separate and then come together, the median is probably the point at which the curves are furthest apart. Again the difference in the medians is not representative, and in this case overestimates the treatment effect: for example, in the case of azacitidine versus low dose ara-C in AML (Dombret et al, 2015) , the difference in medians was 11Á2 versus 6Á4 months, but because the survival curves crossed at 20 months, the hazard ratio was only 0Á90, P = 0Á4. One thing the difference in medians definitely is not is the median improvement in survival: one cannot expect 50% of people to see at least this life gain. From a societal point of view, the area under the curve or between two curves may be helpful -this gives the average number of days gained across the population.
